- Opinion
- [Reporter's view] Godex benefit adequacy will be further di
- by Lee, Tak-Sun Nov 25, 2022 06:05am
- At the Health Insurance Policy Deliberation Committee held on the 23rd, it was decided to further discuss the appropriateness of the salaries of Godex and Imotun at the next deliberation committee. Although the HIRA Drug Benefit Evaluation Committee recognized the appropriateness of the benefit, the final organization, the Health Insurance P
- Opinion
- [Reporter's view] Poor COVID-19 vaccine inducement
- by Nov 22, 2022 06:04am
- "Did you get the COVID-19 vaccine in winter? Mom and dad are the ones who should be vaccinated" The mother answered in a casual manner. "It's okay. I'm in my 60s, so I don't have to get it." "What are you talking about? You have hyperlipidemia. Get it right quickly." "It's okay. I think it'll pass lightly even if I get COVID-19." But will par
- Opinion
- [Reporter's view] Generic drugs can't be me-too drug
- by Kim, Jin-Gu Nov 17, 2022 05:54am
- Controversy is brewing over the government's push to replace the term "generic" with me-too-drug. The KPBMA and the Korean Pharmaceutical Association immediately objected. They stress that it is not enough to contain all the meanings of the term generic in the term copy drug. The backlash from the pharmaceutical industry seems reasonable. Thi
- Opinion
- [Reporter's view] APAP price increase should be quick
- by Lee, Tak-Sun Nov 16, 2022 06:10am
- The government is rushing to raise the upper limit of Acetaminophen which supply and demand are unstable due to COVID-19. The government's plan is to end the review and negotiations as early as this month to reflect the increase plan next month. As the supply and demand of cold medicine continue throughout the year and a large-scale COVID-
- Opinion
- [Reporter’s View] Advanced new drugs, reimb, and patients
- by Eo, Yun-Ho Nov 15, 2022 05:39am
- Some drugs can be prescribed regardless of mutation or receptor status at certain stages of a disease. Other drugs can be prescribed regardless of disease if a certain gene mutation is identified in the patient. As such, the field of pharmaceuticals is evolving at a rapid pace. New drugs that are no longer attached to a specific disease a
- Opinion
- [Reporter's view] COVID-19 demand has disappeared
- by Nov 10, 2022 05:45am
- The boom of pharmaceutical companies, which had benefited from COVID-19, has subsided since the third quarter. Representatively, Roche Group suffered a sharp drop in sales of diagnostic kits and treatments in the third quarter. Roche Group supplies Actemra and Ronapreve, a treatment for COVID-19, and Roche Diagnostics manufactures a COVID-19
- Opinion
- [Reporter’s View] Reimb for SLGT-2i combo still in discussi
- by Eo, Yun-Ho Nov 4, 2022 05:39am
- The agenda has been in the last stages of review for 5 months. At this pace, discussions on expanding reimbursement of SGLT-2 inhibitors as combination therapy may again be passed on to the next year. The discussion on expanding reimbursement of SGLT-2 inhibitors as combination therapy has remained stagnant for a long time. After no progr
- Opinion
- [Reporter’s View]Raising price of cold medicines not enough
- by Lee, Tak-Sun Oct 28, 2022 05:56am
- With the shortage of cold medicines remaining unresolved, the government proposed a drug price increase as its final card. The government decided to first take price adjustment applications for dispensed drugs that contain acetaminophen, which is cheaper than other cold medicines. The government had been implementing support measures
- Opinion
- [Reporter's view] Two plays in the parliamentary audit
- by Kim, Jin-Gu Oct 25, 2022 05:46am
- A Member of Parliament asks about the need to introduce a prescription for active ingredients. Then, whether it was the Minister of Health and Welfare or the Minister of Food and Drug Safety, he replied that he sympathized with the purpose. There is a strong backlash from medical groups. This concludes the play. The same is true this year. Se
- Opinion
- [Reporter’s View] LG Chem’s global two-track strategy
- by Oct 20, 2022 06:02am
- LG Chem announced the acquisition of a US biotech firm on the 18th. LG Chem will invest KRW 800 billion to acquire a 100% stake in AVEO Pharmaceuticals. This is the third-largest in the history of M&As made by domestic pharmaceutical companies. It is also the largest single-company investment along with SK's acquisition of Ampac. AVEO Pharmac
